
MACROLIDES FOR ASTHMA

The Initiative

Clinicians are invited to document outcomes in adolescent and adult patients with asthma for whom they have prescribed macrolides (azithromycin or clarithromycin) or other antibiotics as long-term (3-6 months) adjunctive therapy for severe refractory asthma and new-onset asthma.

What's the goal? To assess what proportion(s) of selected community-based patients with asthma will benefit from prolonged antibiotic treatment.

Why Is This Important?

Macrolides are promising novel therapy for patients with severe, refractory asthma (i.e., patients whose asthma remains poorly controlled despite use of high dose inhaled steroid/LABA or LAMA) (Strength of Recommendation [SOR] B) and new-onset asthma (SOR C). Refer to the [Evidence Review](#) for scientific background. The AMAZES trial demonstrated efficacy of azithromycin in patients with severe, refractory asthma encountered in specialty care. "Real World" evidence is required to better estimate what proportion of comparable community-based patients will respond favorably.

What You Are Being Invited To Do

- Click this link <https://www.fammed.wisc.edu/wren/resources/macrolides-for-asthma> to learn more about the MARCiE registry and to view a Demo version.
- If you treat an adolescent or adult asthma patient with long-term antibiotics, consider entering that patient's data into MARCiE. To gain access to the functional MARCiE registry, submit an application that can be found on the website, or contact the MARCiE administrator directly.
- Prospectively enter de-identified data (no Personal Health Information - PHI) into this human subjects committee-approved registry. Submit data at (i) baseline (i.e., before prescribing), and (ii) every 3-months until 1-year after beginning treatment (~ 3-5 minutes per entry).
- Key Data: (i) basic demographic information (baseline), (ii) the 5-question Asthma Control Test (all time points), and (iii) exacerbations defined as a steroid burst >3 days duration, and/or an unscheduled office or ED visit for worsening asthma, and/or a hospitalization for asthma (all time points).

Compensation

- There is no compensation available.
- You will be kept informed of the registry results.
- You will have access to expert consultation on antibiotic treatment for asthma.

Contact MARCiE Administrator

David Hahn, MD MS Cell: 608-234-3212 Email: dlhahn@wisc.edu
